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Abstract
Aims/hypothesis Our understanding of the transcription
factors that control the development and function of rodent
islet beta cells is advancing rapidly, yet less is known of the
role they play in similar processes in human islets.
Methods To characterise the abundance and regulation of
key proteins involved in glucose-regulated insulin secretion
in human islets, we examined the expression of MAFA,
MAFB, GLUT2 (also known as SLC2A2), βGK (also
known as GCK)a n dPDX1 in isolated, highly purified
human islets with an intact insulin secretory pattern. We
also assessed these features in islets from two different
mouse strains (C57BL/6J and FVB).
Results Compared with mouse islets, human islets secreted
more insulin at baseline glucose (5.6 mmol/l), but less upon
stimulation with high glucose (16.7 mmol/l) or high
glucose plus 3-isobutyl-1-methyl-xanthine. Human islets
had relatively more MAFB than PDX1 mRNA, while
mouse islets had relatively more Pdx1 than Mafb mRNA.
However, v-maf musculoaponeurotic fibrosarcoma onco-
gene homologue (MAF) B protein was found in human islet
alpha and beta cells. This is unusual as this regulator is only
produced in islet alpha cells in adult mice. The expression
of insulin, MAFA, βGK and PDX1 was not glucose-
regulated in human islets with an intact insulin secretory
pattern.
Conclusions/interpretation Our results suggest that human
islets have a distinctive distribution and function of key
regulators of the glucose-stimulated insulin secretion
pathway, emphasising the urgent need to understand the
processes that regulate human islet beta cell function.
Keywords Diabetes.Insulin secretion.Islet.Transcription
factor
Abbreviations
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GSIS Glucose-stimulated insulin secretion
IBMX 3-Isobutyl-1-methyl-xanthine
IEQ Islet equivalent
MAF v-Maf musculoaponeuroticfibrosarcomaoncogene
homologue
NIH National Institutes of Health
PDX1 Pancreatic-duodenal homeobox factor-1
Introduction
Glucose-stimulated insulin secretion (GSIS) by islet beta
cells is a complex process involving glucose transport and
metabolically induced changes in electrical activity that
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ation studies have identified genetic loci associated with
type 2 diabetes, most of which are predicted to alter
pancreatic islet beta cell function [1, 2]. However, the
molecular events that are responsible for normal glucose
regulation of insulin secretion in human beta cells, as well
as the abnormalities caused by the affected type 2 diabetes
genetic loci are poorly defined. This is due partly to deficits
in our knowledge of human beta cell function, with
interspecies differences between the better studied murine
and human islets further confounding this challenge. For
example, human and rodent islets differ in architecture, cell
composition, insulin secretion properties, proliferative
capacity and susceptibility to injury [3–13].
Pancreas and islet development is a complex process
involving signalling pathways and transcription factors that
determine early pancreatic specification and later differen-
tiation [14, 15]. Most information about islet-enriched
transcription factors has emerged from studies in rodent
islet cell lines and genetically modified mice. In contrast,
little is known about the abundance or function of these
transcription factors in human islet cells because of the
absence of human islet cell lines and the low availability of
human islets. Hence, the role of transcription factors in
human beta cell function is largely based on linkage to the
monogenic forms of diabetes, collectively termed MODY
[16]. A challenge in defining how these factors mediate
control of beta cell function is the failure of most mutations
to mimic the human phenotype in rodent models. For
example, while mice and humans heterozygous for Pdx1/
PDX1 mutations are phenotypically similar [17–20], het-
erozygous mutations in Hnf1a, Hnf4a and other MODY
transcription factors do not appear to result in similar islet
dysfunction or diabetes in mice [16]. In fact, v-maf
musculoaponeurotic fibrosarcoma oncogene homologue
(MAF)A is the only other islet-enriched transcription factor
that causes adult beta cell dysfunction and diabetes under
heterozygous conditions in mice [21].
A central role in mouse islet development and/or beta
cell function has been established for the pancreatic-
duodenal homeobox factor-1 (PDX1), MAFA and MAFB
transcription factors [21–27]. PDX1 is not merely important
for regulating insulin secretion in adult islet beta cells, but
is also essential for early exocrine and endocrine progenitor
cell formation, since PDX1-deficient mice and humans
exhibit pancreatic agenesis [22, 28, 29]. MAFA is exclu-
sively produced in the mouse beta cell during development
and in adult animals [25, 30, 31]. In contrast, MAFB, the
only other large MAF family member produced in rodent
islets, is only found in islet alpha cells [26, 27], although its
transient production in developing beta cells is critical to
their formation [26]. MAFA is not required for beta cell
development, probably reflecting compensation by MAFB
[23, 26, 27]. In addition, PDX1 and MAFA are critical
activators of glucose-responsive insulin gene transcription
[24, 25], with transcription factor abundance and/or activity
regulated by glucose in mice [21, 26, 27].
Here, we assessed the functional properties and gene
expression characteristics of key beta cell regulators in
highly purified, glucose-responsive mouse and human islet
preparations. Human islets were found to have distinctive
properties with regard to GSIS, glucose-regulated gene
expression and islet cell distribution of the MAFB
transcription factor.
Methods
Human and mouse islets Mouse islets were isolated from
10 to 12-week-old male FVB and C57BL/6J mice (Jackson
Laboratory, Bar Harbor, ME, USA) as described [32]. Non-
diabetic human islet preparations (n=59) were obtained
from islet isolation centres supported by the Integrated Islet
Distribution Network (http://iidp.coh.org/)[ 33]. We chose
24 preparations from 15 male and nine female donors (age
38.6±2.9 years [range, 17–58], weight 75.8±3.2 kg [range,
46–105 kg], BMI 25.5±0.7 kg/m
2 [range, 21–29.3 kg/m
2])
for further study. Cause of death was listed as: head trauma
(n=7), neurological event (stroke, subarachnoid haemor-
rhage etc., n=10), anoxia (n=1) and unknown (n=6). The
cold ischaemia time before pancreas isolation was 9.4±1.2 h
(range, 1.5–14.5 h). Because the purity of these preparations
varied greatly (30–90% as designated by the isolation
centre), islets were handpicked on the day of arrival prior
to further analysis. Some islet preparations were incubated in
dithizone for 30 min and then viewed by light microscopy
[34]. All animal studies were approved by the Vanderbilt
Institutional Animal Care and Use Committee; de-identified
human samples were obtained as approved by the Vanderbilt
Institutional Review Board.
Assessment of islet function Following isolation, human
islets were usually cultured overnight at the islet isolation
centre before overnight shipment to Vanderbilt. Human and
mouse islets were then cultured in RPMI-1640 containing
10% FBS and 5 mmol/l glucose at 37°C, after which
mRNA or protein was collected. The time for human islet
shipment (approximately 24 h) was included in the culture
time. GSIS of islets was assessed by perifusion [19].
Human islets were perifused on the day of arrival or after
24 h of culture at Vanderbilt. Mouse islets were perifused
after 48 or 72 h of culture; GSIS at both time points was
similar. Perifusion responses were measured using size-
matched mouse and human islets. Insulin secretion was
normalised to islet equivalents (IEQ), representing islet
volume, or normalised to islet insulin content in some
708 Diabetologia (2012) 55:707–718samples. Human islet preparations were designated as having
intact insulin secretion based on the following: stable baseline
responseat5.6 mmol/lglucose,atleasta threefold responseto
16.7 mmol/l glucose and at least a fivefold response to
16.7 mmol/l glucose+100 μmol/l 3-isobutyl-1-methyl-xan-
thine (IBMX). To assess the effects of shipping on islet
function, C57BL/6J mouse islets were isolated at Vanderbilt
then shipped by overnight courier to the University of
Massachusetts and then back to Vanderbilt.
Quantitative RT-PCR Quantitative RT-PCR was performed
using the primer–probe approach from Applied Biosys-
tems (Foster city, CA, USA) using the primers and
conditions described in the electronic supplementary
material (ESM) Methods and ESM Table 1. Quantitative
PCR experiments followed the Minimum Information for
Publication of Quantitative Real-Time PCR Experiments
(MIQE) guidelines [35].
Histological assessment of pancreas and isolated islets Hu-
man and mouse islets were embedded in collagen I (Bectin-
Dickinson, San Jose, CA, USA) and then fixed on ice in
4% (wt/vol.) paraformaldehyde in 1X PBS for 20 min,
followed by three 20-min washes with 1X PBS and 3 h
equilibration in 30% sucrose/1X PBS. The islets were
cryopreserved in Optimum Cutting Temperature Compound
(VWR Scientific Products, Willard, OH, USA). Adult
mouse and human pancreatic tissues were preserved as
described previously [32], except that human pancreas
fixation and washing times were doubled. Human pancreas
samples were obtained from a 23-year-old female donor
and a number of 1-cm
3 specimens dissected from the head,
body and tail of the pancreas. Immunocytochemical studies
on 8-μm cryosections were performed as described previ-
ously [32]. The primary antibody–antigen complex (ESM
Table 2) was visualised using secondary antibodies conju-
gated with Cy2, Cy3 or Cy5 fluorophors (Jackson Immu-
noResearch, West Grove, PA, USA). Islet beta cell death
was measured in histological sections using a kit (ApopTag
Red S7165; Millipore, Bedford, MA, USA). Digital sample
images were acquired with a confocal laser-scanning
microscope (LSM510 META; Carl Zeiss MicroImaging,
Thornwood, NY, USA) at 1 μm optical depth and analysis
performed using a software package (MetaMorph 6.0;
Molecular Devices, Downingtown, PA, USA).
Immunoblotting Whole-islet protein extracts were pre-
pared as described previously [19], with proteins
resolved (25 μg/lane) using a 10% (wt/vol.) NuPAGE
Bis-Tris gel (Invitrogen, Carlsbad, CA, USA) and then
e l e c t r o b l o t t e do nt oI m m o b i l o n-P membrane (Millipore)
[36]. The primary antibody–horseradish peroxidase-
conjugated secondary antibody complex was detected
with a chemiluminescence system (Amersham Bioscien-
ces, Piscataway, NJ, USA). Each membrane was probed
first for MAFA, and then reprobed for MAFB, PDX1 or
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(ESM Fig. 1,E S MT a b l e2).
Unpurified human islets Purified human islets Purified mouse islets
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Fig. 1 Human islets were isolated by handpicking under microscopic
guidance. a An example of a human islet preparation received from an
islet isolation facility and stained by dithizone (DTZ) before and (b)a f t e r
the handpicking procedure. While this example was one of the more
impure preparations studied (stated purity 50%), all islet preparations
contained ductal and acinar fragments. During culture, acinar fragments
rounded up and became similar in size and shape to human islets. These
acinar structures could only be distinguished from islets by the lighter
brown colour of human islets noted by experienced observers. In
contrast, isolated mouse islets were much easier to distinguish from
acinar tissue fragments and could readily be identified for handpicking.
c An example of mouse islets stained by DTZ after handpicking. Scale
bar (a–c) 100 μm. To further evaluate the purity of handpicked islets
(d–f), selected islet preparations were processed for cryosections and
labelled for insulin (Ins, green), glucagon (Glu, green) and α-amylase
(red). The islet cell composition of human and mouse islets was similar
to that observed in a previous report [3]. Note (d) that the size of some
acinar fragments (amylase-positive) is similar to that of islets. Adjacent
sections (g–i) were labelled for insulin (green), glucagon (red) and
somatostatin (Som, blue). Note the difference in islet cell distribution
between human and mouse islets. Scale bar (d–i) 100 μm. j High
enrichment of human (n=6)and(k) FVB mouse islet preparations (n=4)
for beta cells vs acinar cells was demonstrated by quantitative RT-PCR
Diabetologia (2012) 55:707–718 709Statistical analysis The Student’s t test was used for
comparisons of two groups and one-way ANOVA with
Newman–Keuls post-test was applied to multiple group
comparisons. All values represent mean±SEM.
Results
Characteristics of human islet preparations Human islet
preparations were shipped to Vanderbilt University from
various islet isolation facilities as part of the islet
distribution programme supported by the National Institute
of Diabetes and Digestive and Kidney Diseases/National
Institutes of Health (NIH) and Juvenile Diabetes Research
Foundation (http://iidp.coh.org/)[ 33]. Within 24 h of
arrival, human islets were evaluated for insulin secretion
in a cell perifusion system. Appreciating that it is
impossible to isolate human and rodent islets of like age
or under identical conditions, only human islet prepara-
tions with intact insulin secretory response were selected
for this study. Based upon insulin secretory responsive-
ness, the human islet preparations could be divided into
three distinct categories: intact or high responders (n=
33, 56%), lower responders (n=15, 25%) and non-
responders (n=11, 19%). The 24 islet preparations that
had an intact secretory profile and were from non-obese
individuals (BMI 25.5±0.7 kg/m
2;r a n g e ,2 1 –29.3 kg/m
2)
were included in this study.
The islets were handpicked to minimise the ductal and
acinar cell contamination commonly found in human islet
preparations (Fig. 1). Significantly, their purity was now
similar to that of isolated mouse islets as judged by
dithizone staining (Fig. 1a–c), immunocytochemistry
(Fig. 1d–i) and quantitative RT-PCR for insulin and α-
amylase gene expression (Fig. 1j, k). Enrichment of insulin
mRNA in comparison to α-amylase mRNA appeared to be
slightly lower in purified mouse islets (4,783-fold) than in
human islets (7,554-fold), probably because the mRNA
contribution was assessed from only one of the two mouse
insulin genes (i.e. insulin II; Fig. 1j, k). The viability of
mouse and human islets was very similar in TUNEL assays
(both cultured in 5 mmol/l glucose), with a very low level
of beta cell death detected in both species (Fig. 2a). A
caveat is that apoptotic rates are very low in both types of
islets making differences difficult to quantify. The expression
pattern of various apoptosis-related genes was unchanged in
these samples upon incubation in 5 or 11 mmol/l glucose
(Fig. 2b, c). In human islets, this change in glucose
concentration did not affect the expression of apoptosis-
related genes, with only slight differences in Bid and Chop
(also known as Ddit3) mRNA levels being noted in mouse
islets. Collectively, these results indicate that the purity and
viability of the glucose-responsive human and mouse islet
preparations were similar.
Glucose-stimulated insulin secretory profile of human
islets Steady insulin secretion was observed in human
islets at 5.6 mmol/l glucose, increasing rapidly upon
stimulation with 16.7 mmol/l glucose alone or with IBMX
in the dynamic islet perifusion system (Fig. 3a). An intact
second phase of insulin secretion in human islets was also
observed (ESM Fig. 2). However, size-matched human
islets secreted more insulin at the 5.6 mmol/l glucose
baseline and had a lower stimulation index in 16.7 and
16.7 mmol/l glucose plus IBMX than islets from the two
different control mouse strains when normalised to IEQ or
islet insulin content (note that insulin secretion was greater
in FVB than C57BL/6J islets; Fig. 3 a–e, ESM Fig. 3). The
greater basal insulin secretion by human islets does not
represent insulin ‘leaking’ from beta cells, as the perifusion
protocol established a stable baseline and excluded islet
preparations without this property. We also considered the
possibility that these differences between human and mouse
islets might have resulted from the shipping of human islets
from the isolation centre. As a result, C57BL/6J islets
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Fig. 2 Assessment of cell viability in human and mouse islet
preparations. a The numbers of TUNEL-positive beta cells in
representative human (black circles, n=9) and mouse FVB (white
squares, n=4) islet preparations were determined. Analysis was based
on counting approximately 3,000 and 1,200 beta cells per human and
mouse islet sample, respectively; p=0.0673. b The expression profile
of apoptosis-related genes as labelled in human (n=6) and (c) FVB
mouse islets (n=5) cultured in 5 (black bars) or 11 mmol/l (white bars)
glucose. BCLX/Bclx, also known as BCL2L1/Bcl2l1
710 Diabetologia (2012) 55:707–718isolated at Vanderbilt were first cultured for 24 h and then
shipped, by the procedures used for shipping human islets,
to the University of Massachusetts, which then returned
them by overnight courier to Vanderbilt. Notably, similar
GSIS properties were found in the control (unshipped) and
shipped mouse islet preparations (Fig. 3d).
A lower level of insulin secretion in response to glucose
stimulus was also observed in human islets during static
stimulation with glucose (Fig. 3f). The relatively lower
beta/alpha cell ratio of human islets may have contributed
to the reduced human islet insulin secretion levels [3],
although the higher basal insulin secretion by human islets
indicates that other factors are also involved.
Expression and regulation of genes encoding proteins that
are important for GSIS in human islets Quantitative PCR
gene profiling of gene expression in human and mouse
islets showed a similar pattern of islet hormone mRNA
levels relative to glucokinase (Fig. 4a–c), with glucagon
and somatostatin mRNA being relatively greater in human
islets, and insulin (I+II) and Iapp mRNA being greater in
mouse islets. As expected, human islets had a higher level
of GLUT1 (also known as SLC2A1) than of GLUT2 (also
known as SLC2A2) mRNA (Fig. 4a)[ 37, 38].
In contrast to the FVB and C57BL/6J islets, glucokinase,
insulin and somatostatin mRNA expression was not stimulat-
ed by glucose (at 11 or 16.7 mmol/l) in human islets (Fig. 4d–
f; ESM Fig. 4a). Notably, glucose stimulated the expression
of IAPP/Iapp in human and mouse islets (Fig. 4d–f), as
described previously [39]. Mouse islet mRNA expression
was induced as early as 6 h and was very similar in the two
mouse strains, but was stimulated to a lesser degree by
16.7 mmol/l glucose (ESM Fig. 4b,c). The lack of glucose-
stimulated gene expression in human islets paralleled a
difference in beta cell function and insulin secretion following
culture at elevated extracellular glucose [11]. Thus here, for
example, human islets preincubated at 11 mmol/l glucose
also secreted less insulin in response to 16.7 mmol/l glucose
than did mouse islets in static cultures (Fig. 4g,h ) .
Expressionofgenes encodingglucose-regulatedtranscription
factors in human islets Since PDX1 and MAFA are critical
activators of glucose-responsive insulin gene transcription
[21, 24–27], we examined the expression pattern of their
genes in human and mouse islets. Our experimental
approach featured: (1) species-specific PCR primers; (2)
mRNA levels normalised to a number of stably expressed
endogenous mRNAs in human and mouse islets; (3) mRNA
levels expressed relative to βGK/βgk (also known as GCK/
Gck), which was expressed at a very similar level in both
species (delta Ct: 5.053±0.09 vs 4.987±0.11); and (4) use
of several endogenous mRNAs and a stable reference
mRNA (βGK/βgk) to allow comparison of mRNA amount
between human and mouse islets. The expression of MAFA,
MAFB and PDX1 mRNA was greater in human than mouse
islets after culture in 5 mmol/l glucose for 48–72 h (human
n=15, MAFA 1.03±0.11, MAFB 8.17±0.79, PDX1 2.52±
0.29; C57BL/6J n=6, Mafa 0.12±0.02, Mafb 0.41±0.04,
Pdx1 1.31±0.12). MAFA mRNA was less abundant than
PDX1 and MAFB mRNA in human and mouse islets.
Furthermore, human islets had relatively more MAFB
mRNA than PDX1, while mouse islets had relatively more
Pdx1 than Mafb (Fig. 5a–c).
Fig. 3 Insulin secretionin human andmouse islets. a Dynamic glucose-
regulated insulin secretory characteristics of perifused human islets (n=
24), (b)F V Bm o u s ei s l e t s( n=9), (c) C57BL/6J mouse islets (n=8)and
(d) shipped C57BL/6J islets. The insulin concentration was determined
by radioimmunoassay [19]. Note that the scale for the y- a x i si sd i f f e r e n t
for human islets to make the insulin secretory pattern more readily
visible. The amount of insulin secreted was normalised to IEQ, but it
should be realised that islet cell composition in humans is different to
that in mice [3]. Based on our experience with mouse and human islet
preparations, our rationale for normalising insulin to IEQ is described
above (Methods). ESM Fig. 3 shows secreted insulin normalised to islet
insulin content. Here (a–d), the isolated human and mouse islets were
precultured in 5 mmol/l glucose for 72 and 48 h, respectively. Human
islets (a) showed a higher insulin output at basal 5.6 mmol/l glucose
(G5.6) than mouse islets (b–d), and a lower stimulation index at
16.7 mmol/l glucose (G16.7) or 16.7 mmol/l glucose+100 μmol/l IBMX
(G16.7+IBMX). The insert (c) shows basal secretion by human (black
symbols), and FVB and C57BL/6J (white symbols) islets, which in the
latter was similar and appears to overlap. An additional 24 h of culture
of mouse islets did not change the magnitude of the perifusion response;
dynamic GSIS in mouse islets was similar at 48 and 72 h of culture
(data not shown). d To assess the effects of shipping on islet function,
C57BL/6J mouse islets were isolated at Vanderbilt (n=5 islet isolations;
three separate shipments) and cultured for 24 h. Identical islet aliquots
were either cultured in RPMI + 10% FBS (5 mmol/l glucose) or shipped
by overnight courier to the University of Massachusetts using the
shipping containers and conditions used by the Islet Cell Resource
Centers and the Integrated Islet Distribution Network. Upon arrival at
the University of Massachusetts, the shipping container was opened,
labelled with a new shipping label and shipped back by the same
overnight courier. Upon arrival at Vanderbilt, the cultured (black
diamonds) and shipped (white diamonds) islet aliquots were simulta-
neously evaluated in the perifusion system (i.e. at approximately 72 h
after isolation, with approximately 48 h of shipping time). Significantly,
control C57BL/6J islets (cultured for approximately 72 h) and shipped
islets had similar insulin secretory properties, as assessed by AUC per
100 IEQ; p=0.368 for 16.7 mmol/l glucose peak; p=0.322 for glucose+
IBMX peak. e Integrated insulin secretion per 100 IEQ for mouse and
human islets after stimulation with 16.7 mmol/l glucose (black bars) or
16.7 mmol/l glucose+100 μmol/l IBMX (white bars); ***p<0.001 for
comparison with 16.7 mmol/l. One-way ANOVA was used for multiple
group comparisons, with p values as follows: 16.7 mmol/l p<0.001 for
human vs FVB, p>0.05 for human vs C57 and p<0.001 for FVB vs
C57; 16.7 mmol/l glucose+100 μmol/l IBMX p<0.001 for human vs
FVB and human vs C57, and p<0.01 for FVB vs C57. f Static GSIS
was measured in human (n=8) and FVB mouse islets (n=8) exposed to
5 (black bars) or 11 mmol/l (white bars) glucose for an additional 24 h.
Human islets showed significantly higher basal insulin secretion than
mouse, whereas GSIS in human islets increased only three fold vs 30-
fold in mouse islets; *p<0.05 and ***p<0.001 for comparison with
5 mmol/l glucose;
††p<0.01 and
†††p<0.001 for comparison with
human islets

Diabetologia (2012) 55:707–718 711Human and mouse islets were preincubated in
5 mmol/l glucose and then stimulated with 11 mmol/l glucose
to examine whether human MAFA, PDX1 or MAFB
mRNA expression was stimulated by glucose. Under
these conditions, glucose stimulated Mafa and Pdx1
mRNA and protein in mouse islets (Fig. 5e, f,E S M
Fig. 5). MAFA and PDX1 mRNA and protein levels in
human islets were unaffected by these conditions (Fig. 5d
and data not shown) or even after prolonged (96 h)
incubation (ESM Fig. 4a). MAFB/Mafb mRNA levels
were unaffected by glucose in human and mouse islets.
Our data suggest that the inability of human islets to
induce expression of transcriptional mediators of the
insulin gene such as MAFA and PDX1 may limit their
insulin secretory response. We did not note a correlation
between insulin secretion or gene expression and BMI of
the islet donor.
MAFB is expressed in human islet beta cells MAFB mRNA
levels were much higher than those of PDX1 and MAFA in
human islets (Fig. 5a, b). Since MAFB is exclusively
produced in adult mouse alpha cells [26], this might simply
reflect the difference in beta:alpha cell ratio in human islets
[3, 4]. To address this possibility, islet immunohistochem-
ical studies were performed with antibodies to PDX1,
MAFA and MAFB (for details on the biochemical
specificity of the recently generated human MAFA and
MAFB antibodies, see ESM Table 2 and ESM Fig. 1).
The cellular distribution of MAFA and PDX1 in human
and mouse islets was similar, with MAFA only produced in
beta cells (Fig. 6a–d), and PDX1 in beta cells (Fig. 6m–p)
and in a fraction of delta cells (Fig. 6q–t). In contrast, MAFB
was produced in human alpha cells (Fig. 6i–l) and also in a
subset of beta cells (Fig. 6e–h). Importantly, the cellular
distribution pattern was very similar in whole pancreatic
a b
d c
e f
†††
††
10
8
6
4
2
0
40
30
20
10
400
300
200
100
0
0
40
30
20
10
0
40
80
60
40
20
0
30
20
10
0
18
3
2
1
0
21 24 27 30
02 0
G5.6 G5.6
G16.7 G16.7 + IBMX G16.7 G16.7 + IBMX
G16.7 G16.7 + IBMX G16.7 G16.7 + IBMX
G5.6 G5.6 G5.6 G5.6
G5.6 G5.6 G5.6 G5.6 G5.6 G5.6
40 60 80 100
02 0
Human FVB Human FVB C57BL/6J
40 60 80 100
Time (min)
0 2 04 06 08 0 1 0 0
0 2 04 06 08 0 1 0 0
Time (min)
Time (min) Time (min)
I
n
s
u
l
i
n
 
(
n
g
 
[
1
0
0
 
I
E
Q
s
]
−
1
 
m
i
n
−
1
)
I
n
s
u
l
i
n
 
(
n
g
 
[
1
0
0
 
I
E
Q
s
]
−
1
 
m
i
n
−
1
)
I
n
s
u
l
i
n
 
(
n
g
 
[
1
0
0
 
I
E
Q
s
]
−
1
 
m
i
n
−
1
)
I
n
s
u
l
i
n
 
(
n
g
 
[
1
0
0
 
I
E
Q
s
]
−
1
 
m
i
n
−
1
)
I
n
s
u
l
i
n
 
A
U
C
 
(
n
g
/
1
0
0
 
I
E
Q
s
)
I
n
s
u
l
i
n
 
(
n
g
 
i
s
l
e
t
−
1
 
[
2
4
 
h
]
−
1
)
712 Diabetologia (2012) 55:707–718sections, demonstrating that the presence of MAFB in
human beta cells is not an artefact of islet isolation.
Discussion
This study examined a highly selected series of human islet
preparations with an intact insulin secretory pattern in an
effort to establish their gene expression, and physiological
and molecular properties. Two aspects of the human islet
preparations are noteworthy: (1) only preparations that had
intact glucose-stimulated insulin secretory properties were
chosen for subsequent study (representing only 56% of islet
preparations received from the human islet distribution
programmes supported by the NIH and JDRF); and (2) all
human islet preparations analysed were of especially high
purity, quality and viability (Figs 1 and 2), with an
additional handpicking step to greatly reduce acinar and
ductal cell contamination for subsequent gene expression
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Fig. 4 Human islet beta cell-enriched gene expression is not very
responsive to stimulating glucose levels. a Human islets (n=11), or
FVB (b) and C57BL/6J (c) mouse islets (n=4 each) were cultured for
72 or 48 h, respectively, after which total RNA was analysed by
quantitative RT-PCR. mRNA levels for each of the measured islet-
enriched gene products were normalised to four endogenous controls
(i.e. 18S, actin, TFRC/Tfrc and TBP/Tbp in human and C57BL/6J
mice, or 18 s rRNA in FVB mice) and expressed relative to βGK/βgk,
which was set at 1. d Human (n=11), (e) FVB mouse (n=4) and (f)
C57BL/6J mouse (n=4) islets were cultured in 5 mmol/l glucose, and
then in 5 (black bars) or 11 mmol/l (white bars) glucose for an additional 24 h
before RNA analysis. The normalised mRNA level in 11 mmol/l
glucose-cultured islets is expressed relative to 5 mmol/l glucose;
*p<0.05, **p<0.01 and ***p<0.001 compared with islets cultured in
5 mmol/l glucose. SOM/Som,a l s ok n o w na sSST/Sst; GLU/Glu,a l s ok n o w n
as GCG/Gcg. g Human or (h) FVB mouse islets were cultured for 48 or
24 h, respectively, after isolation in 5 mmol/l glucose. Islets were then
cultured in 5 (G5) or 11 mmol/l (G11) glucose for an additional 24 h
(pretreatment) and subsequently challenged with 3 mmol/l (black bars) or
16.7 mmol/l (hatched bars) glucose for 30 min. Insulin released into the
media was measured by RIA. Gene expression in selected mouse
and human islet preparations was similar at 24 and 48 h of culture
(data not shown). *p<0.05 and ***p<0.001 compared with
response to 3 mmol/l glucose;
†††p<0.001 compared with response
of islets incubated in 5 mmol/l glucose for 24 h
Diabetologia (2012) 55:707–718 713studies. Parallel studies were performed in islets from two
mouse strains. The human islets secreted more insulin at
baseline 5.6 mmol/l glucose, but less insulin upon stimu-
lation with 16.7 or 16.7 mmol/l glucose+IBMX. Human
islets also expressed more MAFB than PDX1 mRNA, with
MAFB protein being produced in human islet alpha cells
and beta cells. Stimulation by glucose did not induce the
production of beta cell-enriched gene products in human
islets, including that of the glucose-regulated MAFA and
PDX1 transcriptional mediators of insulin secretion and
beta cell replication in rodents [27, 40, 41]
In recent years, human islets for research have become
more available to a wide range of investigators, thanks to
distribution programmes supported by the NIH and the
Juvenile Diabetes Research Foundation [33]. Several issues
surrounding isolated human islets create considerable
challenges for the provision of islets for transplantation or
research, including donor age and sex, the pre-morbid
condition of the pancreas donor, the isolation procedure and
shipping conditions. While many assays have been used to
assess islet function, we chose the glucose-stimulated
insulin secretory profile in a dynamic cell perifusion system
as our ‘gold standard’ for selection of human islets for
subsequent study. We did this because this method
represents the integration of molecular processes such as
glucose metabolism, Ca
2+ ion channel activity, and secre-
tory vesicle formation and movement. Most previous
studies have not reported the function of the human islet
preparations or the criteria for selecting preparations for
study. The human islets reported on here were chosen from
preparations similar to those distributed to other investi-
gators and reported on in a number of publications, but our
results highlight the fact that independent human islet
preparations cannot be considered to be equivalent. Since
these preparations were selected on the basis of their insulin
secretory pattern, this is likely to have introduced a bias,
and thus the gene expression pattern described by us may
not reflect that of islet preparations with a lower insulin
secretory capacity. Similarly, the insulin secretory pattern of
the selected islet preparations may not be representative of
the situation in humans, where the fold increase in insulin
secretion in vivo is much greater.
These results not only provide important baseline informa-
tion on the function of human islets as currently used for
clinical transplantation and made available for research, but
also outline approaches that could ensure the standardisation
of conditions for selecting human islets for research or
transplantation, or for improving the techniques used for
human islet isolation. Furthermore, the insulin secretory
profile of the human islets used here suggests that improved
islet isolation procedures (including pre-isolation preparation)
are needed and could well improve the function of isolated
islets.Whileitispossiblethatourobservationsinhumanislets
were affected by islet isolation protocol variables or shipping
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Fig. 5 MAFA and PDX1 transcription factor mRNA levels are not
glucose-regulated in cultured human islets. a Human (n=15), (b) FVB
(n=4) and (c) C57BL/6J (n=4) mouse islets were cultured for 72 h
(human) or 48 h (mice), respectively. MAFA/Mafa, MAFB/Mafb and
PDX1/Pdx1 mRNA levels were then quantified by RT-PCR and
expressed relative to MAFA/Mafa. d Human (n=11), (e) FVB (n=4)
and (f) C57BL/6J (n=4) mouse islets were first cultured for 48 h
(human) or 24 h (mouse) in 5 mmol/l glucose, and then for 24 h in 5
(black bars) or 11 mmol/l (white bars) glucose before RNA analysis.
The normalised amount of mRNA in 11 mmol/l glucose-cultured islets
is expressed relative to 5 mmol/l glucose-cultured islets; *p<0.05 and
***p<0.001 compared with islets cultured in 5 mmol/l glucose
714 Diabetologia (2012) 55:707–718conditions, we believe that the unique features we observed
are not due to the viability, purity or quality of our islets,
which were all comparable in their preparation. For example,
the cellular distribution of MAFB was similar in isolated
human islets and pancreatic sections (Fig. 6), suggesting that
this is a distinctive property of human islets.
Any comparison of mouse and human islets would
ideally use the same isolation procedures, and mouse
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Fig. 6 MAFA, PDX1 and MAFB are present in the human islet beta
cell population. The percentage of MAFA-, MAFB- or PDX1-
producing alpha (glucagon, Glu), beta (insulin, Ins) and delta
(somatostatin, Som) cells was determined from the immunohisto-
chemical staining pattern. The intact human pancreas index (a, e, i, m,
q) was 55% MAFA
+ beta cells (n=2,935 [total number of analysed
cells]), 80% PDX1
+ beta cells (n=1,700), 9% MAFB
+ beta cells (n=
1,567) and 40% MAFB
+ alpha cells (n=1,150). MAFA and PDX1
were produced in a larger fraction of beta cells in the mouse pancreas
(c, g, k, o, s): 95% MAFA
+ beta cells (n=2,470), 100% PDX1
+ beta
cells (n=1,516), 0.4% MAFB
+ beta cells (n=670) and 73% MAFB
+
alpha cells (n=327). e–h Arrows point to Ins
+/MAFB
+ cells, arrow-
heads indicate Ins
−/MAFB
+ cells. Scale bar (a)5 0μm applies to all
other panels (b–t). Because, in human islets, beta and non-beta cells
are more intermingled, two criteria were used for cell-counting
purposes to ensure cell identity. First, an islet cell was deemed
positive for nuclear factor or TUNEL only when at least 75% of the
nucleus was surrounded by the cytoplasm labelled for a given
hormone. Second, if the first criterion was met and there was a gap
between the nucleus and the cell cytoplasm, this cell was excluded
from the analysis. Thus, it is possible that due to the stringency of our
counting procedure, counts of cells doubly positive for a hormone and
a transcription factor (especially in human islets) may have been
slightly underestimated
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death status. However, human islets are often isolated
using a continuous isolation procedure and separated in
a refrigerated centrifuge and gradient, a process that is
not feasible based on mouse pancreas size and the
volumes of media needed for the refrigerated apparatus.
Thus while it would be desirable to have mouse islets
isolated in the same fashion from similar donors, we do
not believe it is possible to control for all isolation and
donor variables. Consequently, human islets cannot be
directly compared with mouse islets. Instead, our
findings should be viewed as a characterisation of
human islets with an intact insulin secretory capacity
and not as a direct comparison of mouse and human
islets. Nevertheless, the distinctive features of human
islets (such as MAFB production in islet alpha and beta
cells) suggest important biological differences between
mouse and human islets.
Human islets secreted more insulin at basal glucose
concentrations than mouse islets. These results support the
concept that human islets have a different set-point for
glucose sensing [5, 6, 8, 42]. This hypothesis is also
reinforced by observations showing that human islets have
a lower glucose threshold for Ca
2+ transport [4] and secrete
insulin at lower glucose concentrations than mouse islets [5,
6, 8, 42, 43]. The current report and previous studies
indicate that the threshold for insulin secretion is not only
higher in rodent islets, but that the magnitude of insulin
secretion and range of glucose sensitivity in rodents are
greater than in human islets [5]. Another observation
supporting a different glucose-sensing set-point is that
xenotransplants of human islets into mice establish a lower
blood glucose baseline [44]. The shift in insulin secretion
by human islets to lower glucose concentrations could be
attributed, at least in part, to their preferential production of
high-affinity glucose transporters, compared with rodent
islet beta cells, which mainly produce a low-affinity
transporter [37, 38]. Other potential mechanisms may
involve differences in sensitivity or number of ion channels
downstream from glucokinase [5, 45, 46]. While the current
report and the work of Henquin and colleagues [5] found a
difference in the threshold between mouse and human
islets, the difference in nutrient-stimulated secretion was
greater in our studies. Despite the notable differences in
insulin secretion between human and mouse islets, there are
also many similarities, including the importance of ATP-
sensitive potassium channels, a sustained second phase of
insulin secretion and the effects of interactions between
glucose and amino acids on insulin secretion [5, 43].
Interestingly, we also found that the production of
many beta cell-enriched gene products was only respon-
sive to glucose in mouse islets and that mouse, but not
human islets were capable of increasing beta cell insulin
production and insulin secretory output following acute
and overnight glucose stimulation. In experiments
seeking mechanistic insights into the difference in
glucose-responsive gene expression between mouse and
human islets, we found that the production of transcrip-
tion factors important to glucose-responsive gene tran-
scription in mice, and specifically of PDX1 and MAFA
[21, 23–27], was selectively stimulated by glucose in
mouse islets. Moreover, human islets were found to
produce relatively more MAFA, MAFB and PDX1 mRNA
than mouse islets.
The abundance and/or activity of these islet-enriched
transcription factors in human islets may limit their insulin
secretion to high glucose challenge. The reason why MAFA
and PDX1 expression is unresponsive to glucose stimula-
tion in human islets is unclear, but may reflect differences
in transcription (MAFA [47]) and/or nuclear transport
(PDX1 [48–50]) mechanisms associated with activation in
rodent islets. Alternatively, there may be differences in
molecular events connecting glucose transport and metab-
olism with MAFA/Mafa and PDX1/Pdx1 regulation in
human and mouse beta cells. Additional work is needed
to determine whether these differences in MAFA, MAFB
and PDX1 expression or regulation actually influence
human beta cell activity.
These results emphasise the importance of translating
and integrating discoveries from rodent islets into our
knowledge of human islets in order to expand our
understanding of the regulatory processes involved in
normal human beta cell physiology and islet dysfunc-
tion. Importantly, the question of how to define baseline
human beta cell function in terms of gene expression
and protein production patterns is critical to the
development of beta cells or beta cell surrogates from
alternative cell types for the treatment of type 1 diabetes
and to the provision of insight into islet dysfunction in
type 2 diabetes.
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